SCHEMBL11973087

SCHEMBL11973087

O=[N+]([O-])c1cc(F)c(F)c2cccnc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.65
ALDH1A1 P00352 10/20 0.65
MEN1 O00255 8/20 0.65
KMT2A Q03164 8/20 0.65
KDM4E B2RXH2 7/20 0.65
TDP1 Q9NUW8 6/20 0.65
L3MBTL1 Q9Y468 5/20 0.65
LMNA P02545 4/20 0.65
PKM P14618 3/20 0.65
IDO1 P14902 2/20 0.65
TDO2 P48775 2/20 0.65
CASP6 P55212 2/20 0.65
POLB P06746 2/20 0.65
THRB P10828 1/20 0.65
RECQL P46063 1/20 0.65
BLM P54132 1/20 0.65
CTSB P07858 2/20 0.55
GAA P10253 2/20 0.55
SMN1; SMN2 Q16637 5/20 0.51
HSP90AA1 P07900 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30901429 1.00 MAPT (0.65) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL11972798 0.85 MAPT (0.62) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL8724077 0.81 MAPT (0.67) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL25253980 0.79 MAPT (0.79) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL27190082 0.79 MAPT (1.00) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL18496985 0.79 MAPT (0.62) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL2555260 0.78 MAPT (0.67) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL7960630 0.76 MAPT (0.79) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL10510901 0.76 SLC40A1 (0.51) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL24716165 0.76 MAPT (0.65) MAPTALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117820225-A 3- (8-amino-5, 6-difluoro-4-quinolyl) -2-cyanoacrylate, and preparation method and application thereof 湘潭大学 2024-04-05 CN disclosed
EP-2675526-B1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2017-02-01 EP disclosed
US-9102688-B2 Sulfonaminoquinoline hepcidin antagonists VIFOR (INTERNATIONAL) AG (CH) 2015-08-11 US disclosed
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2014-12-11 US disclosed
EP-2675526-A1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS Vifor (International) AG (CH) 2013-12-25 EP disclosed
WO-2012110603-A1 NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 WO disclosed
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214803-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 MAPT 4801/4885ALDH1A1 3570/4885MEN1 2680/4885
US-20140364424-A1 Novel Sulfonaminoquinoline Hepcidin Antagonists HAMP, SLC40A1, FTH1 MAPT 4801/4885ALDH1A1 3570/4885MEN1 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.